
Ask a doctor about a prescription for BUTILESCOPOLAMINA AUROVITAS 10 mg FILM-COATED TABLETS
Package Leaflet: Information for the Patient
Butylscopolamine Aurovitas 10 mg Coated Tablets EFG
Butylscopolamine Bromide
Read the entire package leaflet carefully before starting to take this medication, as it contains important information for you.
Contents of the Package Leaflet
Butylscopolamine Aurovitas contains a medicine called "Butylscopolamine". This medicine belongs to a group of medicines called "antispasmodics".
This medication is used to relieve cramps in the muscles of the:
Do not take Butylscopolamine Aurovitas:
Do not take this medication if any of the above points apply to you. If you have doubts, consult your doctor or pharmacist before taking this medication.
Warnings and Precautions
Consult your doctor or pharmacist before starting to take this medication if:
If you are not sure if any of the above points apply to you, consult your doctor or pharmacist before taking this medication.
Consult your doctor or pharmacist immediately if you have unexplained abdominal pain that persists or worsens, or occurs with:
Other Medications and Butylscopolamine Aurovitas
Tell your doctor or pharmacist if you are using, have recently used, or may need to use any other medication. This includes medications obtained without a prescription and herbal remedies. This is because butylscopolamine may affect how other medications work. These medications may also affect how butylscopolamine works.
In particular, tell your doctor or pharmacist if you are taking any of the following medications:
If you are not sure if any of the above points apply to you, consult your doctor or pharmacist before taking this medication.
Pregnancy, Breastfeeding, and Fertility
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication.
Pregnancy
There is currently not enough experience with the use of butylscopolamine in pregnant women.
There are not enough animal studies available to indicate possible undesirable or harmful effects in pregnant women. Therefore, you should not use this medication if you are pregnant.
Breastfeeding
The transfer of butylscopolamine bromide, the active ingredient of this medication, to breast milk has not been studied.
Medications of this type may inhibit milk production, and babies may be sensitive to these medications.
When deciding whether to stop breastfeeding or receive treatment with butylscopolamine, your doctor must weigh the benefits of breastfeeding for the child and the benefits of treatment for the mother.
Driving and Using Machines
Administration of this medication may produce side effects such as confusion, blurred vision, drowsiness, etc., which may affect the ability to drive and use machines. No studies have been conducted on the ability to drive and use machines.
Butylscopolamine Aurovitas contains Sucrose
This medication contains sucrose. If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medication.
Always take the medication exactly as your doctor or pharmacist has told you. You should consult with your doctor or pharmacist if you have any doubts.
This medication should not be taken continuously for long periods of time.
Adults and Children over 12 years
The usual dose of this medication for adults and children over 6 years is as follows:
1 to 2 tablets (10 mg to 20 mg), 3 to 5 times a day.
The tablets should be swallowed whole (without chewing or breaking) with liquid.
The effect is observed 15 minutes after taking this medication.
This medication should not be administered daily on a continuous basis or for long periods without investigating the causes of abdominal pain.
No dose adjustment is required in patients with renal and/or hepatic insufficiency.
Follow the administration instructions of the medication contained in this package leaflet or as indicated by your doctor, pharmacist, or nurse. In case of doubt, ask your doctor, pharmacist, or nurse.
Children from 6 to 12 years:
The usual dose is 1 tablet 3 times a day.
This medication is not recommended for children under 6 years.
If you take more Butylscopolamine Aurovitas than you should
Do not take this medication beyond the recommended dose.
If you take more butylscopolamine than you should, you may experience some side effects described in the section "4. Possible side effects".
If this happens, stop taking butylscopolamine and contact your doctor immediately.
In addition, appropriate supportive measures will be applied as needed.
If you have taken more Butylscopolamine Aurovitas than you should, consult your doctor or pharmacist immediately, or call the Toxicology Information Service, phone 91 562 04 20.
If you forget to take Butylscopolamine Aurovitas
If you forget a dose, take it as soon as you remember. However, if it is time for the next dose, skip the missed dose.
Do not take a double dose to make up for a missed dose.
If you have more questions about the use of this medication, consult your doctor or pharmacist.
Like all medications, this medication can cause side effects, although not everyone will experience them. The following side effects may occur with this medication.
Many of the undesirable effects of this medication are associated with its anticholinergic properties. However, these effects are generally mild and limited.
The following may occur:
Uncommon (may affect up to 1 in 100 people):
Rare (may affect up to 1 in 1,000 people):
Frequency not known (cannot be estimated from available data):
Reporting of side effects
If you experience any side effects, consult your doctor, even if they are side effects not listed in this package leaflet. You can also report them directly through the Spanish Medicines Agency's website: www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medication.
Keep out of sight and reach of children.
Do not use this medication after the expiration date stated on the package after CAD. The expiration date is the last day of the month indicated.
Store below 30°C.
Medications should not be disposed of via wastewater or household waste. Dispose of the packaging and any unused medication in the pharmacy's SIGRE collection point. If in doubt, ask your pharmacist how to dispose of the packaging and any unused medication. This will help protect the environment.
Composition of Butylscopolamine Aurovitas
The active substance is butylscopolamine.
Each coated tablet contains 10 mg of butylscopolamine (butylscopolamine bromide).
Excipients:
Core of the tablet: Dicalcium phosphate dihydrate, corn starch, tartaric acid, colloidal anhydrous silica, stearic acid.
Coating: Sucrose, talc (E 553b), hypromellose 2910 (5mPas) (E 464), macrogol 4000 (E 1521), glycerol monostearate (E 471), medium-chain triglycerides, polysorbate 80 (E 433).
Appearance of the Product and Package Contents
White to off-white, circular, biconvex, sugar-coated tablets, smooth on both sides.
Butylscopolamine Aurovitas 10 mg coated tablets EFG are available in blister packs.
Butylscopolamine Aurovitas is available in blister packs.
Package sizes
Blister pack: 10, 20, 30, 40, 50, 60, and 100 coated tablets.
Not all package sizes may be marketed.
Marketing Authorization Holder and Manufacturer
Marketing Authorization Holder:
Aurovitas Spain, S.A.U.
Avda. de Burgos, 16-D
28036 Madrid
Spain
Phone: 91 630 86 45
Fax: 91 630 26 64
Manufacturer:
APL Swift Services (Malta) Ltd,
HF26, Hal Far Industrial Estate, Hal Far
Birzebbugia, BBG 3000, Malta
Or
Generis Farmacêutica S.A., Portugal
Rua de João de Deus, nº 19,
Venda Nova. Amadora
2700 487, Portugal
This medication is authorized in the Member States of the European Economic Area under the following names:
Belgium: Butylhyoscine bromide AB 10 mg coated tablets/comprimés enrobés/berzogene Tabletten
Germany: Butylscopolamin PUREN 10 mg coated tablets
Italy: Scopolamina Aurobindo
Poland: AuroGastro
Portugal: Butylscopolamine Conforpam
Spain: Butylscopolamine Aurovitas 10 mg coated tablets EFG
Date of the last revision of this package leaflet: January 2021
Other sources of information
Detailed and updated information on this medication is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) (http://www.aemps.gob.es/)
The average price of BUTILESCOPOLAMINA AUROVITAS 10 mg FILM-COATED TABLETS in October, 2025 is around 6.12 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for BUTILESCOPOLAMINA AUROVITAS 10 mg FILM-COATED TABLETS – subject to medical assessment and local rules.